Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Advertisement
Cecilia BrownASCO 2025 | June 3, 2025
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Helena Yu, MDASCO 2025 | June 3, 2025
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Laura LitwinConference Coverage | June 2, 2025
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer W. Carlisle, MDASCO 2025 | June 2, 2025
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Lung Cancers Today EditorsASCO 2025 | June 1, 2025
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Laura LitwinASCO 2025 | June 1, 2025
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Lung Cancers Today EditorsImmunotherapy in NSCLC | June 1, 2025
Ivonescimab plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement” in PFS.
Raj Bhardwaj, MDNon-Small Cell Lung Cancer | May 29, 2025
Dr. Sanjay Juneja and Dr. Eric Singhi join a special episode of DDx for a candid conversation on a real patient case.
Stephen V. Liu, MDConference Coverage | June 1, 2025
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Eric Singhi, MDNon-Small Cell Lung Cancer | May 23, 2025
Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations.
Laura LitwinImmunotherapy in NSCLC | May 16, 2025
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
Cecilia BrownNon-Small Cell Lung Cancer | May 14, 2025
The accelerated approval is specifically for patients with high c-Met protein overexpression.
Cecilia BrownNon-Small Cell Lung Cancer | May 13, 2025
The phase 2 platform study has been assessing the combination of belrestotug plus dostarlimab in NSCLC.
Cecilia BrownNon-Small Cell Lung Cancer | May 12, 2025
Researchers synthesized circular RNA encoding NY-ESO-1, which is expressed in a proportion of patients with NSCLC.
Alexander Spira, MD, PhDELCC 2025 | May 8, 2025
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Laura LitwinELCC 2025 | May 1, 2025
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
Cecilia BrownNon-Small Cell Lung Cancer | April 30, 2025
The phase 1 LuCa-MERIT-1 trial is evaluating BNT116, an unmodified RNA-based lipoplex cancer vaccine, with cemiplimab.
Cecilia BrownImmunotherapy in NSCLC | April 29, 2025
Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
Cecilia BrownConference Coverage | April 28, 2025
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Cecilia BrownKRAS+ NSCLC | April 28, 2025
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Advertisement